ATR 1086

About Atrium Therapeutics

Atrium Therapeutics is a clinical-stage biotech focused on pioneering precision RNA medicines for the heart. The company emerged as a spinoff from Novartis's acquisition of Avidity Biosciences, launching with approximately $270 million to advance its novel cardiac-targeted AOC delivery platform. Its strategy is to address the high unmet need in rare genetic cardiomyopathies, with an IND filing for its lead candidate, ATR 1072, planned for H2 2026. Under CEO Kath Gallagher, Atrium combines deep RNA and rare disease expertise to transform cardiology from symptom management to curative genetic intervention.

Therapeutic Areas